Open AccessDosing characteristics of oral treprostinil in real‐world clinical practice
Author(s) -
Balasubramanian Vijay P.,
Messick Chad R.,
Broderick Meredith,
Nelsen Andrew C.
Publication year - 2018
Publication title -
pulmonary circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.791
H-Index - 40
ISSN - 2045-8940
DOI - 10.1177/2045894018770654
Subject(s) - dosing , medicine , treprostinil , tolerability , pharmacokinetics , pharmacology , intensive care medicine , adverse effect , prostacyclin
Pharmacokinetic studies with oral treprostinil demonstrate that three times daily (TID) dosing reduces peak‐to‐trough plasma trepostinil fluctuations compared with twice daily (BID) dosing. TID dosing may allow for faster titration, higher total daily doses, and potentially improve the tolerability of oral trepostinil. This analysis, which looks at the real‐world dosing of oral treprostinil, supports the utility of TID dosing.